Download our latest press release: Cell Therapy Start-Up Seraxis Secures Series A Funding.
Insulin dependent diabetes is a disease that can be treated by the transplant of replacement insulin-producing cells.
To make this a practical reality, a large supply of pure human pancreatic cells that are clinically compliant is required. At Seraxis, we manufacture those cells – derived from a human pancreas – in a certified cleanroom following current Good Manufacturing Practice.
Our therapeutic cells are encapsulated in a proven, bio-compatible material that enables the survival of the cells in the patient without immune suppression.
We are dedicated to developing this technology to be a safe and effective therapy for insulin-dependent diabetes.
Founder and CEO
Will Rust, PhD
Formerly of ATCC, Lonza and ES Cell International, Will Rust has spent his career developing pluripotent stem cells for research and therapeutic applications.
Thank you for your interest in Seraxis. You can find out more about our vison and work by logging in below. If you need a login or would like to find out more about Seraxis, please contact us.
Enter your password:
Seraxis US operations are located in the Germantown Innovation Center, a business incubator program of Montgomery County, Maryland.
20271 Goldenrod Lane, #2085
Germantown, MD 20876
If you would like to learn more about our vision and work, please contact us by filling in the fields below.
You've scrolled 0 Pixels.
Seraxis Pte Ltd © 2013 All rights reserved